Products
A–001
Anthera’s first clinical product‚ A–001 (S–5920/LY315920)‚ is an intravenously administered‚ potent inhibitor of secretory phospholipase 
(
) activity‚ including groups IIA‚ V‚ and X‚ Anthera Pharmaceuticals has initiated a phase 2 clinical study (IMPACTS –
Investigation of the Modulation of Phosholipase in Acute ChesT
Syndrome) with intravenously administered A–001 in hospitalized patients with sickle cell disease who are at–risk for development of acute chest syndrome (an orphan indication). This study will evaluate the safety and efficacy of A–001 as a preventative therapy. At–risk patients will be defined‚ in part‚ by the presence of an elevated serum level. Efficacy will be measured primarily as freedom from both acute chest syndrome and the need for blood transfusion (a common but risky intervention once acute chest syndrome has developed). Read More
A–002
Anthera’s lead cardiovascular product‚ A–002 is an orally administered‚ potent inhibitor of secretory phospholipase ()‚ including groups IIA‚ V‚ and X‚ Anthera has initiated a multi-center phase 2 clinical trial (PLASMA– Phospholipase Levels And Serological Markers of Atherosclerosis) that will examine the effect of A-002 on secretory phospholipase () levels and other well established markers of inflammation and cardiovascular risk in patients with stable coronary artery disease due to underlying atherosclerosis. PLASMA is expected to complete enrollment by the fourth quarter of 2007. According to the American Heart Association‚ coronary heart disease affects nearly 14 million people in the United States and more than 30 million worldwide. Atherosclerosis is a disease of the arteries that results from inflammation and the build-up of plaque under the lining of the blood vessel. This build-up can cause vascular swelling and eventual rupture. levels have been shown to be elevated in patients with both stable and unstable coronary artery disease. Higher levels of the enzyme have been shown to predict an increased risk for future cardiovascular events such as heart attacks and stroke. Read More
A-003
A-003 is a novel inhibitor. It belongs to a novel class of inhibitors and shows excellent efficacy and safety profile. A-003 shows increased potency against enzymes and is orally bioavailable. The compound is under preclinical development for IND enabling studies and will be developed as a second generation inhibitor for the treatment of cardiovascular disease.
A-623
A-623 is an Fc-peptide fusion protein (peptibody) that provides a novel means of inhibiting B-cell maturation and survival. B cells are one part of the human immune system that helps prevent infections. Abnormal activity of the immune system is responsible for autoimmune disease although the exact mechanisms in Systemic Lupus Erythematosus (SLE, lupus) is not yet established. Dosing of SLE subjects with A-623 in two Phase 1 clinical studies has been completed. Anthera anticipates initiating a multi-center, clinical Phase 2 study in 2008 that will evaluate the efficacy, safety, and tolerability of A-623 treatment in SLE patients. Systemic Lupus Erythematosus is a chronic autoimmune disease of unknown etiology in which an individual’s immune system attacks the body’s own tissues. Lupus is a debilitating disease that can affect the skin, joints, and multiple organ systems including the lungs, kidney, heart and blood. Lupus causes inflammation, atherosclerosis, organ damage/failure (e.g. lupus nephritis), and can be life threatening. Read More